Table 1.
Patient demographics and baseline characteristics
| SRI | MiRI | ||||
|---|---|---|---|---|---|
| Edoxaban 15 mg | Edoxaban 15 mg | Fondaparinux 1.5 mg | Edoxaban 30 mg | ||
| CL CR (mL/min) | ≥15 to <20 | ≥20 to <30 | ≥20 to <30 | ≥50 to ≤80 | |
| N = 7 | N = 22 | N = 20 | N = 30 | ||
| Female, n (%) | 6 (85.7) | 19 (86.4) | 20 (100.0) | 27 (90.0) | |
| Age, yr | |||||
| mean (SD) | 91.7 (7.1) | 86.5 (4.3) | 85.7 (8.9) | 78.1 (6.5) | |
| <75, n (%) | 0 | 0 | 2 (10.0) | 8 (26.7) | |
| ≥75, n (%) | 7 (100.0) | 22 (100.0) | 18 (90.0) | 22 (73.3) | |
| Weight, kg | |||||
| mean (SD) | 39.4 (3.8) | 44.3 (8.9) | 46.1 (8.0) | 54.5 (11.1) | |
| ≤60, n (%) | 7 (100.0) | 21 (95.5) | 18 (90.0) | 22 (73.3) | |
| >60, n (%) | 0 | 1 (4.5) | 2 (10.0) | 8 (26.7) | |
| CLCR, mL/min | |||||
| median | 18.7 | 27.6 | 26.2 | 62.7 | |
| min–max | 15.3–20.0 | 20.4–30.0 | 22.8–30.0 | 50.7–79.8 | |
| Surgery, n (%) | |||||
| TKA | 0 | 5 (22.7) | 6 (30.0) | 9 (30.0) | |
| THA | 0 | 1 (4.5) | 4 (20.0) | 8 (26.7) | |
| HFS | 7 (100.0) | 16 (72.7) | 10 (50.0) | 13 (43.3) | |
| Physiotherapy use, n (%) | |||||
| Present | 7 (100.0) | 22 (100.0) | 20 (100.00) | 30 (100.0) | |
| Elastic stocking | 7 (100.0) | 21 (95.5) | 19 (95.0) | 23 (76.7) | |
| Intermittent pneumatic compression | 5 (71.4) | 8 (36.4) | 9 (45.0) | 19 (63.3) | |
| Concomitant use of NSAIDs, n (%) | 6 (85.7) | 20 (90.9) | 18 (90.0) | 29 (96.7) | |
| Concomitant use of P-gp inhibitor, n (%) | 1 (14.3) | 0 (0.0) | 0 (0.0) | 1 (3.3) | |
CLCR = creatinine clearance (calculated using the Cockcroft-Gault formula); HFS = hip fracture surgery; MiRI = mild renal impairment; NSAIDs = nonsteroidal anti-inflammatory drugs; P-gp = P-glycoprotein; SRI = severe renal impairment; THA = total hip arthroplasty; TKA = total knee arthroplasty.